Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 325 to 333 of 333 entries
Sorted by: Best Match Show Resources per page
Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis.

BMJ open

Mottram R, Knerr WL, Gallacher D, Fraser H, Al-Khudairy L, Ayorinde A, Williamson S, Nduka C, Uthman OA, Johnson S, Tsertsvadze A, Stinton C, Taylor-Phillips S, Clarke A.
PMID: 34848507
BMJ Open. 2021 Nov 30;11(11):e046660. doi: 10.1136/bmjopen-2020-046660.

OBJECTIVE: Attendance at population-based breast cancer (mammographic) screening varies. This comprehensive systematic review and meta-analysis assesses all identified patient-level factors associated with routine population breast screening attendance.DESIGN: CINAHL, Cochrane Library, Embase, Medline, OVID, PsycINFO and Web of Science were...

Cite
Mottram R, Knerr WL, Gallacher D, et al. Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis. BMJ Open. 2021;11(11):e046660doi: 10.1136/bmjopen-2020-046660.
Mottram, R., Knerr, W. L., Gallacher, D., Fraser, H., Al-Khudairy, L., Ayorinde, A., Williamson, S., Nduka, C., Uthman, O. A., Johnson, S., Tsertsvadze, A., Stinton, C., Taylor-Phillips, S., & Clarke, A. (2021). Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis. BMJ open, 11(11), e046660. https://doi.org/10.1136/bmjopen-2020-046660
Mottram, Rebecca, et al. "Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis." BMJ open vol. 11,11 (2021): e046660. doi: https://doi.org/10.1136/bmjopen-2020-046660
Mottram R, Knerr WL, Gallacher D, Fraser H, Al-Khudairy L, Ayorinde A, Williamson S, Nduka C, Uthman OA, Johnson S, Tsertsvadze A, Stinton C, Taylor-Phillips S, Clarke A. Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis. BMJ Open. 2021 Nov 30;11(11):e046660. doi: 10.1136/bmjopen-2020-046660. PMID: 34848507; PMCID: PMC8634222.
Copy Download .nbib Format: NLM
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis.

Cancers

Koch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Hohberger B, Kähler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schell B, Schlaak M, Terheyden P, Thoms KM, Schuler-Thurner B, Ugurel S, Ulrich J, Utikal J, Weichenthal M, Ziller F, Berking C, Heppt MV, On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma.
PMID: 34283061
Cancers (Basel). 2021 Jul 04;13(13). doi: 10.3390/cancers13133359.

BACKGROUND: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM...

Cite
Koch EAT, Petzold A, Wessely A, et al. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133359.
Koch, E. A. T., Petzold, A., Wessely, A., Dippel, E., Gesierich, A., Gutzmer, R., Hassel, J. C., Haferkamp, S., Hohberger, B., Kähler, K. C., Knorr, H., Kreuzberg, N., Leiter, U., Loquai, C., Meier, F., Meissner, M., Mohr, P., Pföhler, C., Rahimi, F., Schadendorf, D., Schell, B., Schlaak, M., Terheyden, P., Thoms, K. M., Schuler-Thurner, B., Ugurel, S., Ulrich, J., Utikal, J., Weichenthal, M., Ziller, F., Berking, C., Heppt, M. V., & On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma. (2021). Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers, 13(13), . https://doi.org/10.3390/cancers13133359
Koch, Elias A T, et al. "Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133359
Koch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Hohberger B, Kähler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schell B, Schlaak M, Terheyden P, Thoms KM, Schuler-Thurner B, Ugurel S, Ulrich J, Utikal J, Weichenthal M, Ziller F, Berking C, Heppt MV, On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers (Basel). 2021 Jul 04;13(13). doi: 10.3390/cancers13133359. PMID: 34283061; PMCID: PMC8268645.
Copy Download .nbib Format: NLM
Influence of Interfacial Bonding on the Mechanical and Impact Properties Ring-Opening Metathesis Polymer (ROMP) Silica Composites.

ACS applied materials & interfaces

Tran NT, Patterson BA, Harris DE, Napadensky E, Lenhart JL, Knorr DB, Bain ED.
PMID: 33190488
ACS Appl Mater Interfaces. 2020 Nov 25;12(47):53342-53355. doi: 10.1021/acsami.0c16280. Epub 2020 Nov 15.

Polymers formed by ring-opening metathesis polymerization (ROMP) such as poly(dicyclopentadiene) (pDCPD) exhibit a technologically desirable combination of high toughness, high glass transition temperature, and outstanding low-temperature performance. However, because of their nonpolar molecular structure, they tend to suffer from...

Cite
Tran NT, Patterson BA, Harris DE, et al. Influence of Interfacial Bonding on the Mechanical and Impact Properties Ring-Opening Metathesis Polymer (ROMP) Silica Composites. ACS Appl Mater Interfaces. 2020;12(47):53342-53355doi: 10.1021/acsami.0c16280.
Tran, N. T., Patterson, B. A., Harris, D. E., Napadensky, E., Lenhart, J. L., Knorr, D. B., & Bain, E. D. (2020). Influence of Interfacial Bonding on the Mechanical and Impact Properties Ring-Opening Metathesis Polymer (ROMP) Silica Composites. ACS applied materials & interfaces, 12(47), 53342-53355. https://doi.org/10.1021/acsami.0c16280
Tran, Ngon T, et al. "Influence of Interfacial Bonding on the Mechanical and Impact Properties Ring-Opening Metathesis Polymer (ROMP) Silica Composites." ACS applied materials & interfaces vol. 12,47 (2020): 53342-53355. doi: https://doi.org/10.1021/acsami.0c16280
Tran NT, Patterson BA, Harris DE, Napadensky E, Lenhart JL, Knorr DB, Bain ED. Influence of Interfacial Bonding on the Mechanical and Impact Properties Ring-Opening Metathesis Polymer (ROMP) Silica Composites. ACS Appl Mater Interfaces. 2020 Nov 25;12(47):53342-53355. doi: 10.1021/acsami.0c16280. Epub 2020 Nov 15. PMID: 33190488.
Copy Download .nbib Format: NLM
Pyroptosis in Steatohepatitis and Liver Diseases.

Journal of molecular biology

Knorr J, Wree A, Feldstein AE.
PMID: 34592216
J Mol Biol. 2021 Sep 27;167271. doi: 10.1016/j.jmb.2021.167271. Epub 2021 Sep 27.

Pyroptosis is an inflammatory form of regulated cell death, which functions in the clearance of intracellularly replicating pathogens by cell lysis in order to induce further immune response. Since the discovery of the gasdermin (GSDM) family, pyroptosis has attracted...

Cite
Knorr J, Wree A, Feldstein AE. Pyroptosis in Steatohepatitis and Liver Diseases. J Mol Biol. 2021;167271doi: 10.1016/j.jmb.2021.167271.
Knorr, J., Wree, A., & Feldstein, A. E. (2021). Pyroptosis in Steatohepatitis and Liver Diseases. Journal of molecular biology, 167271. https://doi.org/10.1016/j.jmb.2021.167271
Knorr, Jana, et al. "Pyroptosis in Steatohepatitis and Liver Diseases." Journal of molecular biology vol. (2021): 167271. doi: https://doi.org/10.1016/j.jmb.2021.167271
Knorr J, Wree A, Feldstein AE. Pyroptosis in Steatohepatitis and Liver Diseases. J Mol Biol. 2021 Sep 27;167271. doi: 10.1016/j.jmb.2021.167271. Epub 2021 Sep 27. PMID: 34592216.
Copy Download .nbib Format: NLM
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.

European urology

Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C, Morgenstern A, Eiber M.
PMID: 33293081
Eur Urol. 2021 Mar;79(3):343-350. doi: 10.1016/j.eururo.2020.11.013. Epub 2020 Dec 05.

BACKGROUND: Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time.OBJECTIVE: To report the safety and activity of alpha-emitting Ac-225-PSMA-617 RLT in...

Cite
Feuerecker B, Tauber R, Knorr K, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2020;79(3):343-350doi: 10.1016/j.eururo.2020.11.013.
Feuerecker, B., Tauber, R., Knorr, K., Heck, M., Beheshti, A., Seidl, C., Bruchertseifer, F., Pickhard, A., Gafita, A., Kratochwil, C., Retz, M., Gschwend, J. E., Weber, W. A., D'Alessandria, C., Morgenstern, A., & Eiber, M. (2021). Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. European urology, 79(3), 343-350. https://doi.org/10.1016/j.eururo.2020.11.013
Feuerecker, Benedikt, et al. "Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA." European urology vol. 79,3 (2021): 343-350. doi: https://doi.org/10.1016/j.eururo.2020.11.013
Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C, Morgenstern A, Eiber M. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2021 Mar;79(3):343-350. doi: 10.1016/j.eururo.2020.11.013. Epub 2020 Dec 05. PMID: 33293081.
Copy Download .nbib Format: NLM
Antarctic icebergs reorganize ocean circulation during Pleistocene glacials.

Nature

Starr A, Hall IR, Barker S, Rackow T, Zhang X, Hemming SR, van der Lubbe HJL, Knorr G, Berke MA, Bigg GR, Cartagena-Sierra A, Jiménez-Espejo FJ, Gong X, Gruetzner J, Lathika N, LeVay LJ, Robinson RS, Ziegler M.
PMID: 33442043
Nature. 2021 Jan;589(7841):236-241. doi: 10.1038/s41586-020-03094-7. Epub 2021 Jan 13.

The dominant feature of large-scale mass transfer in the modern ocean is the Atlantic meridional overturning circulation (AMOC). The geometry and vigour of this circulation influences global climate on various timescales. Palaeoceanographic evidence suggests that during glacial periods of...

Cite
Starr A, Hall IR, Barker S, et al. Antarctic icebergs reorganize ocean circulation during Pleistocene glacials. Nature. 2021;589(7841):236-241doi: 10.1038/s41586-020-03094-7.
Starr, A., Hall, I. R., Barker, S., Rackow, T., Zhang, X., Hemming, S. R., van der Lubbe, H. J. L., Knorr, G., Berke, M. A., Bigg, G. R., Cartagena-Sierra, A., Jiménez-Espejo, F. J., Gong, X., Gruetzner, J., Lathika, N., LeVay, L. J., Robinson, R. S., Ziegler, M. (2021). Antarctic icebergs reorganize ocean circulation during Pleistocene glacials. Nature, 589(7841), 236-241. https://doi.org/10.1038/s41586-020-03094-7
Starr, Aidan, et al. "Antarctic icebergs reorganize ocean circulation during Pleistocene glacials." Nature vol. 589,7841 (2021): 236-241. doi: https://doi.org/10.1038/s41586-020-03094-7
Starr A, Hall IR, Barker S, Rackow T, Zhang X, Hemming SR, van der Lubbe HJL, Knorr G, Berke MA, Bigg GR, Cartagena-Sierra A, Jiménez-Espejo FJ, Gong X, Gruetzner J, Lathika N, LeVay LJ, Robinson RS, Ziegler M. Antarctic icebergs reorganize ocean circulation during Pleistocene glacials. Nature. 2021 Jan;589(7841):236-241. doi: 10.1038/s41586-020-03094-7. Epub 2021 Jan 13. PMID: 33442043.
Copy Download .nbib Format: NLM
Impact of Removing the Race Coefficient in Renal Function Estimate Equations on Drug Dosage Recommendations.

The Annals of pharmacotherapy

Miller J, Knorr JP.
PMID: 33866823
Ann Pharmacother. 2022 Jan;56(1):44-51. doi: 10.1177/10600280211010228. Epub 2021 Apr 17.

BACKGROUND: The appropriateness of including the race coefficient in glomerular filtration rate (GFR) equations in Black patients is debated, and the impact on drug dosing is unknown.OBJECTIVE: This study explored the impact of removing the race coefficient on drug...

Cite
Miller J, Knorr JP. Impact of Removing the Race Coefficient in Renal Function Estimate Equations on Drug Dosage Recommendations. Ann Pharmacother. 2021;56(1):44-51doi: 10.1177/10600280211010228.
Miller, J., & Knorr, J. P. (2022). Impact of Removing the Race Coefficient in Renal Function Estimate Equations on Drug Dosage Recommendations. The Annals of pharmacotherapy, 56(1), 44-51. https://doi.org/10.1177/10600280211010228
Miller, Janine, and Knorr, John P. "Impact of Removing the Race Coefficient in Renal Function Estimate Equations on Drug Dosage Recommendations." The Annals of pharmacotherapy vol. 56,1 (2022): 44-51. doi: https://doi.org/10.1177/10600280211010228
Miller J, Knorr JP. Impact of Removing the Race Coefficient in Renal Function Estimate Equations on Drug Dosage Recommendations. Ann Pharmacother. 2022 Jan;56(1):44-51. doi: 10.1177/10600280211010228. Epub 2021 Apr 17. PMID: 33866823.
Copy Download .nbib Format: NLM
Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review.

Journal of geriatric psychiatry and neurology

Knorz AL, Quante A.
PMID: 34476990
J Geriatr Psychiatry Neurol. 2021 Sep 03;8919887211044746. doi: 10.1177/08919887211044746. Epub 2021 Sep 03.

IMPORTANCE: Alzheimer's disease (AD) is a complex neurodegenerative disorder and the most prevalent cause of dementia. In spite of the urgent need for more effective AD drug therapy strategies, evidence of the efficacy of combination therapy with existing drugs...

Cite
Knorz AL, Quante A. Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. J Geriatr Psychiatry Neurol. 2021;8919887211044746doi: 10.1177/08919887211044746.
Knorz, A. L., & Quante, A. (2021). Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. Journal of geriatric psychiatry and neurology, 8919887211044746. https://doi.org/10.1177/08919887211044746
Knorz, Adrian L, and Quante, Arnim. "Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review." Journal of geriatric psychiatry and neurology vol. (2021): 8919887211044746. doi: https://doi.org/10.1177/08919887211044746
Knorz AL, Quante A. Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. J Geriatr Psychiatry Neurol. 2021 Sep 03;8919887211044746. doi: 10.1177/08919887211044746. Epub 2021 Sep 03. PMID: 34476990.
Copy Download .nbib Format: NLM
Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).

EClinicalMedicine

Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, Knorr B, Lawrence D, Ossa D, Wang W, Maspero JF.
PMID: 33997741
EClinicalMedicine. 2021 Apr 25;35:100847. doi: 10.1016/j.eclinm.2021.100847. eCollection 2021 May.

BACKGROUND: These studies assessed the efficacy and safety of fevipiprant, an oral antagonist of the prostaglandin DMETHODS: ZEAL-1 (NCT03215758) and ZEAL-2 (NCT03226392) are two replicate, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group studies in which fevipiprant 150 mg once...

Cite
Castro M, Kerwin E, Miller D, et al. Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine. 2021;35:100847doi: 10.1016/j.eclinm.2021.100847.
Castro, M., Kerwin, E., Miller, D., Pedinoff, A., Sher, L., Cardenas, P., Knorr, B., Lawrence, D., Ossa, D., Wang, W., & Maspero, J. F. (2021). Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine, 35100847. https://doi.org/10.1016/j.eclinm.2021.100847
Castro, Mario, et al. "Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)." EClinicalMedicine vol. 35 (2021): 100847. doi: https://doi.org/10.1016/j.eclinm.2021.100847
Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, Knorr B, Lawrence D, Ossa D, Wang W, Maspero JF. Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine. 2021 Apr 25;35:100847. doi: 10.1016/j.eclinm.2021.100847. eCollection 2021 May. PMID: 33997741; PMCID: PMC8099656.
Copy Download .nbib Format: NLM
Showing 325 to 333 of 333 entries